BACKGROUND: Correlation between erbB-2 expression, histologic type of gastric carcinoma, and survival after curative resection was evaluated. METHODS: Paraffin-embedded specimens from 120 patients who underwent curative resection of gastric carcinoma were analyzed immunohistochemically for the expression of erbB-2. RESULTS: Enhanced erbB-2 expression correlated with tumor stage and depth of invasion. Well-differentiated adenocarcinomas had a higher incidence of erbB-2 expression than did poorly differentiated carcinomas. Survival rates of 33 patients with erbB-2-positive carcinomas were significantly lower than those of 87 with erbB-2-negative carcinomas (p < 0.001). Survival rates of patients with well-differentiated adenocarcinomas that were erbB-2 positive were significantly lower than those that were erbB-2 negative (p < 0.001). However, the presence of erbB-2 was not associated with altered survival in 46 patients with poorly differentiated carcinomas. Multivariate analysis of all 120 patients revealed that independent predictors of recurrent disease include nodal involvement (p = 0.003) and erbB-2 expression (p = 0.0051). CONCLUSIONS: Our results suggest that erbB-2 expression is a new marker associated with poor prognosis in well-differentiated gastric adenocarcinomas.
BACKGROUND: Correlation between erbB-2 expression, histologic type of gastric carcinoma, and survival after curative resection was evaluated. METHODS:Paraffin-embedded specimens from 120 patients who underwent curative resection of gastric carcinoma were analyzed immunohistochemically for the expression of erbB-2. RESULTS: Enhanced erbB-2 expression correlated with tumor stage and depth of invasion. Well-differentiated adenocarcinomas had a higher incidence of erbB-2 expression than did poorly differentiated carcinomas. Survival rates of 33 patients with erbB-2-positive carcinomas were significantly lower than those of 87 with erbB-2-negative carcinomas (p < 0.001). Survival rates of patients with well-differentiated adenocarcinomas that were erbB-2 positive were significantly lower than those that were erbB-2 negative (p < 0.001). However, the presence of erbB-2 was not associated with altered survival in 46 patients with poorly differentiated carcinomas. Multivariate analysis of all 120 patients revealed that independent predictors of recurrent disease include nodal involvement (p = 0.003) and erbB-2 expression (p = 0.0051). CONCLUSIONS: Our results suggest that erbB-2 expression is a new marker associated with poor prognosis in well-differentiated gastric adenocarcinomas.
Authors: Michael Luis; Ana Tavares; Liliana S Carvalho; Lúcio Lara-Santos; António Araújo; Ramon Andrade de Mello Journal: World J Gastroenterol Date: 2013-10-14 Impact factor: 5.742
Authors: Stefan Kubicka; Christiane Claas; Sven Staab; Florian Kühnel; Lars Zender; Christian Trautwein; Siegfried Wagner; Karl Lenhard Rudolph; Michael Manns Journal: Dig Dis Sci Date: 2002-01 Impact factor: 3.199
Authors: Abbas Ghaderi; Mohammad Vasei; S A Maleck-Hosseini; Behronz Gharesi-Fard; Maliheh Khodami; Mehrnoosh Doroudchi; Helmout Modjtahedi Journal: Pathol Oncol Res Date: 2003-02-11 Impact factor: 3.201
Authors: M A Gordon; H M Gundacker; J Benedetti; J S Macdonald; J C Baranda; W J Levin; C D Blanke; W Elatre; P Weng; J Y Zhou; H J Lenz; M F Press Journal: Ann Oncol Date: 2013-03-22 Impact factor: 32.976